Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Idexx Laboratories (IDXX)

Idexx Laboratories (IDXX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 57,123,004
  • Shares Outstanding, K 79,851
  • Annual Sales, $ 3,898 M
  • Annual Income, $ 887,870 K
  • EBIT $ 1,306 M
  • EBITDA $ 1,436 M
  • 60-Month Beta 1.67
  • Price/Sales 14.00
  • Price/Cash Flow 57.29
  • Price/Book 36.42

Options Overview Details

View History
  • Implied Volatility 44.34% (+0.52%)
  • Historical Volatility 18.39%
  • IV Percentile 94%
  • IV Rank 72.88%
  • IV High 52.99% on 04/08/25
  • IV Low 21.07% on 08/12/25
  • Expected Move (DTE 34) 65.54 (9.16%)
  • Put/Call Vol Ratio 0.68
  • Today's Volume 195
  • Volume Avg (30-Day) 150
  • Put/Call OI Ratio 0.81
  • Today's Open Interest 4,314
  • Open Int (30-Day) 4,424
  • Expected Range 649.83 to 780.91

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 2.93
  • Number of Estimates 7
  • High Estimate 3.00
  • Low Estimate 2.87
  • Prior Year 2.62
  • Growth Rate Est. (year over year) +11.83%

Price Performance

See More
Period Period Low Period High Performance
1-Month
661.89 +8.08%
on 01/02/26
726.41 -1.52%
on 01/13/26
+22.19 (+3.20%)
since 12/16/25
3-Month
622.08 +15.00%
on 10/29/25
769.98 -7.09%
on 11/26/25
+78.03 (+12.24%)
since 10/16/25
52-Week
356.14 +100.87%
on 04/09/25
769.98 -7.09%
on 11/26/25
+286.75 (+66.90%)
since 01/16/25

Most Recent Stories

More News
Lowest-Dose Radiography Meets Next-Level Imaging: IDEXX Launches ImageVue DR50 Plus

A fully connected imaging ecosystem – centralized access, integrated workflows, and AI-powered imaging to accelerate diagnosis and elevate care

IDXX : 715.37 (+0.46%)
IDEXX Advances the Future of Veterinary Cancer Care with Comprehensive Mast Cell Tumor Testing for Dogs

Cancer Dx expansion and inVue Dx FNA combine preventive screening and rapid, in-clinic diagnosis, enabling veterinarians and pet owners to act with confidence

IDXX : 715.37 (+0.46%)
IDEXX Announces CEO Succession

Michael Erickson, PhD, to Succeed Jay Mazelsky as President and CEO; Mazelsky to Serve as Executive Chair of the Board of Directors

IDXX : 715.37 (+0.46%)
IDEXX Laboratories to Release 2025 Fourth Quarter and Full Year Financial Results

IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 fourth quarter and full year financial results for Monday, February...

IDXX : 715.37 (+0.46%)
What to Expect From IDEXX Laboratories’ Next Quarterly Earnings Report?

IDEXX Laboratories is expected to release its fiscal fourth-quarter earnings soon, and analysts project a double-digit earnings increase.

XLV : 155.74 (-0.78%)
$SPX : 6,940.01 (-0.06%)
IDXX : 715.37 (+0.46%)
How Is IDEXX Laboratories’ Stock Performance Compared to Other Health Care Stocks?

Although IDEXX Laboratories has outperformed the healthcare sector over the past year, analysts remain cautiously optimistic about the stock’s prospects.

XLV : 155.74 (-0.78%)
ZTS : 124.65 (-0.50%)
IDXX : 715.37 (+0.46%)
Danaher Stock: Is DHR Underperforming the Healthcare Sector?

Despite Danaher’s underperformance relative to the healthcare sector, Wall Street analysts remain strongly optimistic about the stock’s prospects.

XLV : 155.74 (-0.78%)
IDXX : 715.37 (+0.46%)
DHR : 235.99 (-1.63%)
Thermo Fisher Scientific Stock: Is TMO Outperforming the Health Care Sector?

Thermo Fisher Scientific has outperformed the broader healthcare sector over the past year, and analysts continue to hold a strongly bullish view on its growth prospects.

XLV : 155.74 (-0.78%)
TMO : 618.72 (-0.95%)
IDXX : 715.37 (+0.46%)
What Are Wall Street Analysts' Target Price for IDEXX Laboratories Stock?

IDEXX Laboratories has considerably outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.

XHE : 89.57 (-0.10%)
$SPX : 6,940.01 (-0.06%)
JPM : 312.47 (+1.04%)
IDXX : 715.37 (+0.46%)
Stock Index Futures Plunge on Valuation Concerns

December S&P 500 E-Mini futures (ESZ25) are down -1.01%, and December Nasdaq 100 E-Mini futures (NQZ25) are down -1.31% this morning as quarterly results from AI bellwether Palantir failed to impress investors...

NVDA : 186.23 (-0.44%)
ANET : 129.83 (-0.58%)
SPOT : 504.50 (-0.70%)
SRPT : 21.13 (-0.84%)
GEBN.Z.EB : 616.200 (+0.95%)
MU : 362.75 (+7.76%)
FN : 494.45 (-0.63%)
NQZ25 : 25,132.79s (+0.42%)
AMGN : 330.41 (+0.12%)
PFE : 25.65 (-0.93%)
EDEN.P.DX : 17.730 (-1.55%)
SHOP : 155.81 (-1.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

IDEXX Laboratories, Inc. is a developer, manufacturer and distributor of products and services primarily for the companion animal veterinary, livestock and poultry, water testing and dairy markets. The company also sells a series of portable electrolytes and blood gas analyzers for the human point-of-care...

See More

Key Turning Points

3rd Resistance Point 728.88
2nd Resistance Point 724.41
1st Resistance Point 719.89
Last Price 715.37
1st Support Level 710.91
2nd Support Level 706.44
3rd Support Level 701.92

See More

52-Week High 769.98
Last Price 715.37
Fibonacci 61.8% 611.89
Fibonacci 50% 563.06
Fibonacci 38.2% 514.23
52-Week Low 356.14

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar